TUBIZE-FIN

Research TUBIZE-FIN (TUB.BR) on Bullrun: market cap EUR 7.99B, dividend yield 0.6%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 7.99B; dividend yield is 0.6%.

Peer valuation comparison

Latest dividend yield is 0.6% versus a Healthcare sector median of 2.05% (70.7% below).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025EUR 0EUR 93.23M-EUR 3.37Mn/a2.09EUR 368.07KEUR 0EUR 1.89B
FY2024EUR 0EUR 90.10M-EUR 2.07Mn/a2.02EUR 1.43MEUR 41.30MEUR 1.84B
FY2023EUR 0EUR 88.15M-EUR 2.05Mn/a1.98EUR 574.84KEUR 79.20MEUR 1.80B
FY2022EUR 0EUR 85.17M-EUR 2.11Mn/a1.91EUR 1.07MEUR 47.80MEUR 1.75B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-09-23EUR 7.99Bn/an/an/a

Dividend history

Latest trailing dividend snapshot: yield 0.6%.

YearDividends/share
FY20251.04 EUR
FY20240.97 EUR
FY20230.86 EUR
FY20220.75 EUR
FY20210.68 EUR

About TUBIZE-FIN

Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous system. The company was founded in 1928 and is based in Brussels, Belgium.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is TUBIZE-FIN's market cap?

TUBIZE-FIN's market capitalization is EUR 7.99B.

Does TUBIZE-FIN pay a dividend?

TUBIZE-FIN has a dividend yield of 0.6%.

What does TUBIZE-FIN do?

Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous system. The company was founded in 1928 and is based in Brussels, Belgium.